Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

BACKGROUND: The SHIVA trial is a multicentric randomised proof-of-concept phase II trial comparing molecularly targeted therapy based on tumour molecular profiling vs conventional therapy in patients with any type of refractory cancer. Results of the feasibility study on the first 100 enrolled patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Tourneau, C, Paoletti, X, Servant, N, Bièche, I, Gentien, D, Rio Frio, T, Vincent-Salomon, A, Servois, V, Romejon, J, Mariani, O, Bernard, V, Huppe, P, Pierron, G, Mulot, F, Callens, C, Wong, J, Mauborgne, C, Rouleau, E, Reyes, C, Henry, E, Leroy, Q, Gestraud, P, La Rosa, P, Escalup, L, Mitry, E, Trédan, O, Delord, J-P, Campone, M, Goncalves, A, Isambert, N, Gavoille, C, Kamal, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090722/
https://www.ncbi.nlm.nih.gov/pubmed/24762958
http://dx.doi.org/10.1038/bjc.2014.211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090722/
https://www.ncbi.nlm.nih.gov/pubmed/24762958
http://dx.doi.org/10.1038/bjc.2014.211

Ejemplares similares